市場調查報告書
商品編碼
1433435
全球外骨骼市場 2023-2030Global Exoskeleton Market 2023-2030 |
預計在預測期內(2024-2031年),全球外骨骼市場將以 12.4%的CAGR成長。推動外骨骼市場的重要因素包括脊髓損傷發生率的上升,外骨骼研發投資的增加以及政府政策的凝聚力。根據國家脊髓損傷統計中心(NSCISC)2023年的資料,美國創傷性脊髓損傷(tSCI)的年發病率最新估計約為每百萬人 54 例,相當於每年約新增 18,000 例 tSCI 病例年。此外,私營和公共部門對外骨骼技術開發的投資不斷增加,進一步促進了市場成長。2023年 12月,劍橋外骨骼開發商 Verve Motion 籌集了2000 萬美元的 B 輪資金,以擴大其 SafeLift 軟外骨骼的規模。 SafeLift 像背包一樣穿著,利用即時運動感應和機器人輔助,可減輕典型工作日工人背部 40%的壓力。
全球外骨骼市場依類型、移動性和最終用戶進行細分。根據類型,市場分為動力外骨骼和被動外骨骼。根據移動性,市場分為移動和固定/固定。此外,根據最終用戶,市場分為醫療、工業和軍事。在這些類型中,動力外骨骼細分市場預計將佔據很大的市場佔有率,這主要歸因於減少工業中的身體壓力、提高生產力和復健支持。
在行動領域中,行動細分市場預計將在全球外骨骼市場中佔據相當大的佔有率。此細分市場的成長歸因於為行動不便的個人提供站立能力、促進獨立性和提高生活品質,以及移動外骨骼技術的不斷進步和監管部門的批准。此外,主要參與者也在不同地區拓展業務,以滿足移動外骨骼的需求。例如,2023年 10月,Wandercraft 與凱斯勒基金會合作,在美國推出了 Atalante X 移動外骨骼的商業運作。這款免持設備經 FDA 批准用於中風康復,利用自平衡技術和遊戲化功能進行物理治療。在2022年 12月獲得 FDA 批准 Atalante 用於中風復原後,Wandercraft 策略性地擴大了在美國的足跡。該公司在紐約建立了新的營運基地,以增強其市場影響力並支援 Atalante 在該地區的部署。該設備於2019年獲准在歐盟使用,此後已用於治療 650 多名患者,進行了 5,000 多次治療。
全球外骨骼市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國、亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,由於外骨骼在軍事和國防應用中的使用越來越多,包括士兵增強和負重輔助,預計歐洲將在全球市場中佔據顯著佔有率,這有助於歐洲市場的擴張。
在所有地區中,北美地區預計在預測期內將以相當大的CAGR成長。區域市場的成長歸因於醫療保健中擴大採用外骨骼進行復健和政府的支持性舉措,以及工業環境中擴大採用外骨骼以提高工人的安全和生產力。根據美國勞工統計局的資料,2022年美國有5,486起致命工傷,比2021年的5,190起增加了5.7%。致命工傷率為每10萬名全職當量工人中有3.7人死亡,到2021年,每10 萬名全職員工中的3.6 人將增加。此外,外骨骼製造商、技術公司和研究機構之間不斷加強的合作也促進了該地區的創新和市場成長。2024年 1月,理查德和洛恩希爾生物醫學工程系的 Ming Wu 教授獲得了伊利諾伊大學芝加哥分校和 OSF Healthcare 的合作資助,用於創建用於護理的外骨骼。該計畫目的是為護理人員製造外骨骼,以避免與重複性任務和長時間輪班相關的腰痛和受傷風險。
服務外骨骼市場的主要公司包括 Bionik Laboratories、Bioness Inc.、Cyberdyne Inc.、Ekso Bionics Holdings, Inc.、ReWalk Robotics Ltd. 等。市場參與者透過各種策略(包括併購、夥伴關係、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2022年 6月,Ekso Bionics 為其專為多發性硬化症(MS)患者設計的 EksoNR 機器人外骨骼獲得了 FDA 510(k)許可。這標誌著 FDA 首次批准外骨骼復健用於多發性硬化症患者,擴大了該設備的應用範圍。
Global Exoskeleton Market Size, Share & Trends Analysis Report by Type (Powered Exoskeletons and Passive Exoskeletons), by Mobility (Mobile and Fixed/Stationary), and by End-User (Medical, Industrial, and Military), Forecast Period (2024-2031)
The global exoskeleton market is anticipated to grow at a CAGR of 12.4% during the forecast period (2024-2031). Significant factors contributing to the exoskeleton market include the growing incidence rate of spinal cord injuries, increasing investment in R&D of the exoskeleton, and cohesive government policies. As per the National Spinal Cord Injury Statistical Center (NSCISC) 2023, the most recent estimate of the annual incidence of traumatic spinal cord injury (tSCI) is approximately 54 cases per one million people in the US, which equals about 18,000 new tSCI cases each year. Additionally, growing investments from private and public sectors in the development of exoskeleton technologies further contribute to market growth. In December 2023, Verve Motion, a Cambridge-based exoskeleton developer, raised $20 million in Series B funding to scale its SafeLift soft exoskeleton. SafeLift, worn like a backpack, utilizes real-time motion sensing and robotic assistance to alleviate 40% of the strain on a worker's back during a typical workday.
The global exoskeleton market is segmented by type, mobility, and end-user. Based on the type, the market is sub-segmented into powered exoskeletons and passive exoskeletons. Based on mobility, the market is sub-segmented into mobile and fixed/stationary. Further, based on the end-user, the market is sub-segmented into medical, industrial, and military. Among the types, the powered exoskeletons sub-segment is projected to hold a significant share of the market, primarily attributed to reducing physical strain in industries, improving productivity, and rehabilitation support.
Among the mobility, the mobile sub-segment is expected to hold a considerable share of the global exoskeleton market. The segmental growth is attributed to providing individuals with mobility impairments the ability to stand, promoting independence and improved quality of life, and continuous advancements in mobile exoskeleton technology, and regulatory approvals. In addition, the key players are also expanding their business in different regions to cater to the demand for mobile exoskeletons. For instance, in October 2023, Wandercraft launched commercial operations in the US for its Atalante X mobility exoskeleton, partnering with the Kessler Foundation. FDA-approved for stroke rehabilitation, the hands-free device utilizes self-balancing technology and gamified features for engaging in physiotherapy. After securing FDA approval in December 2022 for Atalante's utilization in stroke rehabilitation, Wandercraft strategically expanded its footprint in the US. The company established a new operational base in New York to enhance its market presence and support the deployment of Atalante in the region. The device was approved for use in the EU in 2019 and has since been used to treat over 650 patients across over 5,000 sessions.
The global exoskeleton market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to the growing use of exoskeletons in military and defense applications, including soldier augmentation and load-bearing assistance, which contributes to market expansion in Europe.
Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. The regional market growth is attributed to the growing adoption of exoskeletons in healthcare for rehabilitation and supportive government initiatives and the increasing adoption of exoskeletons in industrial settings to enhance worker safety and productivity. According to the US Bureau of Labor Statistics, there were 5,486 fatal work injuries recorded in the US in 2022, marking a 5.7% increase from the 5,190 recorded in 2021. The fatal work injury rate was 3.7 fatalities per 100,000 full-time equivalent workers, up from 3.6 per 100,000 full-time equivalents in 2021. In addition, increasing collaborations between exoskeleton manufacturers, technology firms, and research institutions bolster innovation and market growth in the region. In January 2024, Prof. Ming Wu at the Richard and Loan Hill Department of Biomedical Engineering received a collaborative grant from the University of Illinois Chicago and OSF Healthcare to create an exoskeleton for nursing. The project aimed to create an exoskeleton for nursing staff to avoid lower back pain and injury risks associated with repetitive tasks and long shifts.
The major companies serving the exoskeleton market include Bionik Laboratories, Bioness Inc., Cyberdyne Inc., Ekso Bionics Holdings, Inc., ReWalk Robotics Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2022, Ekso Bionics received FDA 510(k) clearance for its EksoNR robotic exoskeleton designed for Multiple Sclerosis (MS) patients. This marked the first FDA clearance for exoskeleton rehabilitation use in MS patients, broadening the device's application.